Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Autran

Showing results (171-180 of 173) with videos related to

Pageof 18
Sort By:
You have reached the last page of results.This site can display upto 173 results.
AIDS Research and Human Retroviruses|May 20, 1999
Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le SidaD Salmon-Céron, J L Excler, L Finkielsztejn, et al.
Ebiomedicine|December 24, 2017
What Is the most Important for Elite Control: Genetic Background of Patient, Genetic Background of Partner, both or neither? Description of Complete Natural History within a Couple of MSMM Bendenoun, A Samri, V Avettand-Fènoël, et al.
The Journal of Infectious Diseases|January 13, 2012
Single-nucleotide polymorphism-defined class I and class III major histocompatibility complex genetic subregions contribute to natural long-term nonprogression in HIV infectionJ Guergnon, C Dalmasso, P Broet, et al.
Pageof 18

Showing results (171-180 of 173) with videos related to

Sort By:
Pageof 18
You have reached the last page of results.This site can display upto 173 results.
AIDS Research and Human Retroviruses|May 20, 1999
Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le SidaD Salmon-Céron, J L Excler, L Finkielsztejn, et al.
Ebiomedicine|December 24, 2017
What Is the most Important for Elite Control: Genetic Background of Patient, Genetic Background of Partner, both or neither? Description of Complete Natural History within a Couple of MSMM Bendenoun, A Samri, V Avettand-Fènoël, et al.
The Journal of Infectious Diseases|January 13, 2012
Single-nucleotide polymorphism-defined class I and class III major histocompatibility complex genetic subregions contribute to natural long-term nonprogression in HIV infectionJ Guergnon, C Dalmasso, P Broet, et al.
Pageof 18